The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Waldenström’s PFS unaffected by ibrutinib dose reduction, for now
In some cases, ibrutinib dose reduction is required to manage levels of toxicity; however, it remains unclear if this adversely affects PFS in Waldenström macroglobulinemia (WM) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jorge Castillo, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the study looking to address this, revealing that patients older than 65 years and those with major responses were more likely to have a dose reduction, before stating that ibrutinib dose reduction did not significantly impact PFS; nevertheless, as this was the result of only a short follow-up, time will tell.
